Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Principal Investigator
Name
Johannes Reiter
Degrees
Ph.D.
Institution
Stanford University
Position Title
Assistant Professor
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-581
Initial CDAS Request Approval
Feb 7, 2020
Title
A new mathematical model for the computation of optimal screening frequencies for lung and colorectal cancer
Summary
An estimated 1.9 million new cancer cases will be diagnosed this year in the United States alone. While recent advancements in tumor treatment and management have improved overall survival rates, similar progresses in cancer prevention and early detection are still needed to further decrease morbidity and mortality from this disease.

To this end, a promising tool is represented by liquid biopsies. This term generally refers to non-invasive tests aiming to detect and analyze specific biomarkers in bodily fluids. Clinical trials are currently underway for several cancer types to assess the full potential and limitations of liquid biopsies for disease surveillance and tracking over time.

For both screening and relapse monitoring purposes, however, a more general problem arises: even if a test with high sensitivity and specificity is designed and developed, its efficacy in detecting a disease might depend on the times at which the test is taken. We have developed a stochastic model of cancer evolution and ctDNA shedding to determine the optimal testing frequency. We provide a new way to optimize the testing frequency by minimizing the expected tumor detection size for a fixed number of liquid biopsies. With small adjustments, this setup adapts to both cancer screening and cancer relapse detection.
Aims

We aim to analyze the PLCO dataset to validate our framework. In particular, we will exploit the dataset to:
- infer key parameters of our model, especially for lung cancer;
- compare the model predictions with clinical observations;
- analyze the differences in the results yielded by our framework for different cancer types.

Collaborators

Johannes Reiter - Stanford University
Stefano Avanzini - Stanford University